acetoacetic acid has been researched along with Morbid Obesity in 1 studies
acetoacetic acid : A 3-oxo monocarboxylic acid that is butyric acid bearing a 3-oxo substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three clinical studies were conducted: a bariatric surgery cohort study of participants with morbid obesity who underwent either Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) studied over four and twelve weeks, and two randomized placebo-controlled, crossover double blind studies of liraglutide vs." | 5.69 | Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. ( Alexandrou, A; Angelidi, AM; Connelly, MA; Kokkinos, A; Mantzoros, CS; Mingrone, G; Sanoudou, D, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angelidi, AM | 1 |
| Kokkinos, A | 1 |
| Sanoudou, D | 1 |
| Connelly, MA | 1 |
| Alexandrou, A | 1 |
| Mingrone, G | 1 |
| Mantzoros, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Study of the Effects of Roux en Y Gastric Bypass and Sleeve Gastrectomy on Postprandial Gut Hormone Responses, Glycemia and Lipid Profile, Weight Loss, and Indices of Cardiovascular Risk[NCT03851874] | 28 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI[NCT01562678] | Phase 4 | 28 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Saxenda: Underlying Mechanisms and Clinical Outcomes[NCT02944500] | Phase 4 | 28 participants (Actual) | Interventional | 2016-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period. (NCT01562678)
Timeframe: 18 days of Liraglutide or placebo treatment
| Intervention | z-scores of activation in cortex (Mean) |
|---|---|
| Liraglutide | -0.42 |
| Placebo | 0.53 |
1 trial available for acetoacetic acid and Morbid Obesity
| Article | Year |
|---|---|
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |
Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Citrates; Cohort Studies; Diabetes Mellitus, Type 2; Gastrecto | 2023 |